A slow-cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy

Basal cell carcinoma (BCC) is the most frequent cancer in humans and results from constitutive activation of the Hedgehog pathway1. Several Smoothened inhibitors (Smoi) are used to treat Hedgehog-mediated malignancies, including BCC and medulloblastoma2. Vismodegib, a Smoi, leads to BCC shrinkage in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Danés, Adriana, Larsimont, Jean-Christophe, Liagre, Mélanie, Muñoz-Couselo, Eva, Lapouge, Gaëlle, Brisebarre, Audrey, Dubois, Christine, Suppa, Mariano, Sukumaran, Vijayakumar, del Marmol, Véronique, Tabernero, Josep, Blanpain, Cédric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295195/
https://www.ncbi.nlm.nih.gov/pubmed/30297799
http://dx.doi.org/10.1038/s41586-018-0603-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295195/
https://www.ncbi.nlm.nih.gov/pubmed/30297799
http://dx.doi.org/10.1038/s41586-018-0603-3

Ejemplares similares